Biggs et al. reported that prostate-specific plasma EV (identified based on PSMA expression on the EV membrane) numbers were suitable to identify prostate cancer patients with high risk, and those with metastatic disease [169]. This evidence concerns the gene FOLH1 and prostate carcinoma.